<DOC>
	<DOCNO>NCT01461044</DOCNO>
	<brief_summary>This observational study evaluate safety efficacy triple negative HR+ patient HER2-metastatic locally advanced breast cancer treat Avastin ( bevacizumab ) first line therapy least 12 month without disease progression least 12 month . Data collect retrospectively ( diagnosis inclusion study ) 18 month study start .</brief_summary>
	<brief_title>An Observational Study Avastin ( Bevacizumab ) Patients With HER2-metastatic Locally Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Adult patient , &gt; /=18 year age HER2metastatic breast cancer locally advance breast cancer Patients Avastin first line therapy administer least 12 month Patients without disease progression begin Avastin treatment least 12 month Patients willing give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>